Cornerstone Mulls Next Steps for Lixivaptan After CRL

With government offices still hampered by the cleanup from Hurricane Sandy, the FDA was several days late responding to Cornerstone Therapeutics Inc.'s new drug application for lixivaptan. The decision, reported Thursday, was no shocker.